Primagen and OncoGenome link up on cancer tests:
This article was originally published in Clinica
Executive Summary
Dutch company Primagen is to design and develop multiple molecular cancer diagnostic tests for Liege, Belgian firm OncoGenome Sciences. Primagen will endeavour to design five genomics-based diagnostic tests that can detect cancer much earlier and more accurately than current tests, the Amsterdam firm says. The tests should also be able to predict and monitor response to therapy for optimal, more individualised treatment decisions. Commenting on the collaboration, OncoGenome's CEO Herman Spolders said: "We plan to start dedicated end-development of clinical diagnostic testing services and kits of the molecular tests designed by Primagen over a year, followed by clinical trials as the first activities in the FDA approval procedure." OncoGenome has recently completed a E12m ($12.8m) funding round (see Clinica No 1050, p 15).
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.